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included age = 49 years, disease duration = 9.5 years, TJC = 24,
SJC = 14, HAQ-DI = 1.0, and PASI = 7.9. Forty-four percent of
patients were female. Pearson correlation coefﬁcients between
variables were -0.6 (HAQ-DI and SF-6D, p < 0.05), -0.2 (PASI
and SF-6D, p < 0.05) and 0.1 (HAQ-DI and PASI, p = 0.2) As
determined by multiple linear regression, signiﬁcant independent
predictors of PsA-related QoL (in descending order of impor-
tance) were: functional loss (HAQ-DI), severity of psoriasis
(PASI), and TJC (all p < 0.05). SJC was not a signiﬁcant predic-
tor of QoL in PsA. CONCLUSIONS: In patients with PsA, the
main determinants of QoL measured were degree of disease-
related functional loss and severity of skin disease. In contrast to
ﬁndings in rheumatoid arthritis, joint counts were of secondary
importance. These ﬁndings have important implications for eco-
nomic evaluations of new treatments for PsA.
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OBJECTIVE: the management of hemophilic patients is very
expensive. This situation becomes extreme when patients
develop inhibitors, which comprises the effectiveness of treat-
ment, with potential increase of morbidity and mortality. We
compared cost of care and Health-Related Quality-of-Life
(HRQoL) between hemophilic patients with (INHIB+) and those
without (INHIB-) inhibitors. METHODS: INHIB+ was enrolled
in the Cost Of Care Inhibitors Study (COCIS) [Gringeri et al,
Blood 2003]; INHIB- was enrolled in the Cost Of Care of
HEmophilia (COCHE) study: naturalistic, multicentre, longitu-
dinal studies involving patients enrolled at the Italian Hemo-
philia Centres. Results are reported on: cost with clotting factor
concentrates evaluated from the Italian National Health Service’s
point of view, HRQoL evaluated with the EuroQol and Short
Form-36. The bootstrap resampling method (5000 samples) was
applied as a statistical approach to compare the two groups.
RESULTS: INHIB+ was 52: median age 35 years (15–64), 100%
with hemophilia A, 94.2% with severe hemophilia, 98% high
responders. INHIB- was 232: median age 34.3 years (18–74),
86.6% with hemophilia A, 72.4% with severe hemophilia.
Patients with inhibitors bled signiﬁcantly less frequently than
patients without inhibitors (p < 0.0001): INHIB+ reported on
average 0.59 hemorrhages/patient/month to joints and muscles
(median = 0.33, 0–2.61), INHIB- had 2.10 hemorrhages/
patient/month (median = 1.44, 0–26.0). On average 0.16 chirur-
gical interventions/patient/year were performed to INHIB+
(19.2% patients involved), 0.35 interventions/patient/year were
performed to INHIB- (16.4% patients involved). Overall, cost
of care for INHIB+ was 17.725 €/patient/month; cost for
INHIB- was 8.341 €/patient/month, 16.473 €/patient/month to
treat patients on prophylaxis and 4.2 to treat those on demand
regimen. in the two groups HRQoL was similar, concerning both
the physical and mental components. CONCLUSION: treatment
for INHIB+ patients is much more costly than that for INHIB-
patients, is effective and allows reaching good levels of HRQoL,
similar to those perceived by INHIB- patients.
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OBJECTIVES: Information on costs of multiple myeloma (MM)
management is scarce. The objective of this incidence–based
cost–of–illness study was to assess direct medical costs and cost
drivers in major disease phases: primary diagnosis (PD), recur-
rent (RCD) or refractory disease (RFD). METHODS: A retro
projected chart review was performed in 9 centres (n = 176, ran-
domly selected patients) in Belgium (n = 56), France (n = 41),
UK (n = 40) and Germany (n = 39). Costs were calculated from
the payer’s perspective by multiplying resource utilization with
local unit costs from ofﬁcial sources. Data collection covered the
2–year period (or up to death) following treatment initiation in
2001. Descriptive statistics were performed on costs. Cost
drivers were identiﬁed using a linear mixed regression model.
RESULTS: The sample included 49% PD, 41% RCD and 10%
RFD. Stem–cell or bone marrow transplantation rate was 52%.
For PD, RCD and RFD respectively, 2–year costs were €59,648,
€47,039 and €46,362, of which approximately 80% incurred
during the ﬁrst year. Transplantation rates differed between
countries (39%–73%) and disease phase (68%, 40% and 28%
in PD, RCD and RFD). Descriptive cost analysis showed poten-
tial impact of phase, survival, transplantation and centre. The
regression model suggested costs to increase with number of
transplantations (p < 0.0001), increasing stage at diagnosis (p =
0.0097), occurrence of complications (p = 0.0194) and decreas-
ing age (p = 0.0004). The mean total cost was €31,612
(€26,300–€34,300) in patients without transplantation com-
pared to €59,915 (€53,000–€66,600) in the transplant popula-
tion. CONCLUSION: The study provided insight into cost
drivers in MM. The main therapeutic cost driver was transplan-
tation. Important centre–speciﬁc variation exists in transplanta-
tion accessibility. In addition, there is a lack of consensus on
transplantation practices. Since the current study was undersized
to represent national transplantation rates, further research is
needed to establish real life transplantation rates in different MM
settings.
UH3
OVERACTIVE BLADDER IN MALES: A GROWING HEALTH
AND ECONOMIC BURDEN
Reeves P1, Kopp Z2, Milsom I3,Artibani W4,Abrams P5
1Fourth Hurdle Consulting Ltd, London, UK; 2Pﬁzer Inc, New York,
NY, USA; 3Sahlgrenska University Hospital, Göteborg, Sweden;
4Monoblocco Ospedaliero, Padova, Italy; 5Bristol Urological Institute,
BRISTOL, UK
OBJECTIVE: To estimate the current and future economic
burden of Overactive Bladder (OAB) in males in ﬁve European
countries. METHOD: A cost of illness model estimated the
annual cost of managing OAB in Germany, Italy, Spain, Sweden
and the UK by deﬁning a locally relevant package of care and
multiplying resources used by country-speciﬁc unit cost data.
The total cost of OAB in males was calculated by multiplying
the estimated prevalence of OAB in males by the estimated
annual direct cost of OAB management. The model also esti-
mated the likely economic impact of increasing numbers of
elderly men. RESULTS: The prevalence of OAB is known to be
highest in the elderly and is commonly perceived to affect mostly
women. However, in this study, 9.6m males aged >40 were esti-
